WO2024069240A3 - Thérapie de combinaison de protéines de fusion se liant à cd38 - Google Patents

Thérapie de combinaison de protéines de fusion se liant à cd38 Download PDF

Info

Publication number
WO2024069240A3
WO2024069240A3 PCT/IB2023/000653 IB2023000653W WO2024069240A3 WO 2024069240 A3 WO2024069240 A3 WO 2024069240A3 IB 2023000653 W IB2023000653 W IB 2023000653W WO 2024069240 A3 WO2024069240 A3 WO 2024069240A3
Authority
WO
WIPO (PCT)
Prior art keywords
fusion protein
binding fusion
cancer
combination therapy
protein combination
Prior art date
Application number
PCT/IB2023/000653
Other languages
English (en)
Other versions
WO2024069240A2 (fr
Inventor
Sabrina Collins
Xavier PAROT
Shuang Wu LI
Laura THESILLAT-VERSMEE
Richard LABOTKA
Jim Sampson
Neeraj Gupta
Shining WANG
Kaveri SURYANARAYAN
Original Assignee
Takeda Pharmaceutical Company Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Company Limited filed Critical Takeda Pharmaceutical Company Limited
Publication of WO2024069240A2 publication Critical patent/WO2024069240A2/fr
Publication of WO2024069240A3 publication Critical patent/WO2024069240A3/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2497—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing N- glycosyl compounds (3.2.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/02—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2) hydrolysing N-glycosyl compounds (3.2.2)
    • C12Y302/02005—NAD+ nucleosidase (3.2.2.5)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne des méthodes de traitement du cancer (par exemple, un cancer exprimant CD38 tel qu'un myélome multiple) à l'aide d'une protéine de fusion se liant à CD38 comprenant un anticorps anti-CD38 fusionné à une ou plusieurs protéines d'interféron alpha-2b atténuées en combinaison avec un ou plusieurs (par exemple, un, deux ou plus) agents pour traiter le cancer. Dans certains modes de réalisation, le cancer est un myélome multiple. Dans certains modes de réalisation, lesdits un ou plusieurs agents comprennent un médicament immunomodulateur (par exemple, le lénalidomide et/ou le pomalidomide) et/ou des inhibiteurs de protéasome (par exemple, le bortézomib et/ou le carfilzomib).
PCT/IB2023/000653 2022-09-29 2023-09-28 Thérapie de combinaison de protéines de fusion se liant à cd38 WO2024069240A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263411286P 2022-09-29 2022-09-29
US63/411,286 2022-09-29

Publications (2)

Publication Number Publication Date
WO2024069240A2 WO2024069240A2 (fr) 2024-04-04
WO2024069240A3 true WO2024069240A3 (fr) 2024-05-23

Family

ID=89378574

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2023/000653 WO2024069240A2 (fr) 2022-09-29 2023-09-28 Thérapie de combinaison de protéines de fusion se liant à cd38

Country Status (1)

Country Link
WO (1) WO2024069240A2 (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012041800A1 (fr) * 2010-09-27 2012-04-05 Morphosys Ag Utilisation d'un anticorps anti-cd38 et de lénalidomide ou de bortézomib pour traiter le myélome multiple et le lymphome non hodgkinien
US20150313965A1 (en) * 2014-05-01 2015-11-05 Teva Pharmaceuticals Australia Pty, Ltd Combination of Lenalidomide and Polypeptide Construct, and Uses Thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1360189A1 (fr) 2001-01-25 2003-11-12 Millennium Pharmaceuticals, Inc. Formulation de composes d'acide boronique
US7232818B2 (en) 2004-04-15 2007-06-19 Proteolix, Inc. Compounds for enzyme inhibition
BR112017008880A2 (pt) 2014-10-29 2018-07-10 Teva Pharmaceuticals Australia Pty Ltd variantes de interferon a2b

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012041800A1 (fr) * 2010-09-27 2012-04-05 Morphosys Ag Utilisation d'un anticorps anti-cd38 et de lénalidomide ou de bortézomib pour traiter le myélome multiple et le lymphome non hodgkinien
US20150313965A1 (en) * 2014-05-01 2015-11-05 Teva Pharmaceuticals Australia Pty, Ltd Combination of Lenalidomide and Polypeptide Construct, and Uses Thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SARAH L. POGUE ET AL: "Targeting Attenuated Interferon-[alpha] to Myeloma Cells with a CD38 Antibody Induces Potent Tumor Regression with Reduced Off-Target Activity", PLOS ONE, vol. 11, no. 9, 9 September 2016 (2016-09-09), pages e0162472, XP055637284, DOI: 10.1371/journal.pone.0162472 *

Also Published As

Publication number Publication date
WO2024069240A2 (fr) 2024-04-04

Similar Documents

Publication Publication Date Title
CR20220396A (es) Anticuerpos y proteínas de fusión que se unen a ccr8 y usos de estos
NO20070052L (no) Fremgangsmate for behandling av multippel sklerose
MX2021008267A (es) Tratamiento agudo y tratamiento rapido de la cefalea usando anticuerpos anti-cgrp.
DE60229979D1 (fr)
MX2023002540A (es) Anticuerpo biespecifico contra el cumulo de diferenciacion 3 (cd3) y el cumulo de diferenciacion 20 (cd20) en terapia combinada para el tratamiento del linfoma folicular.
MX2021008268A (es) Tratamiento de cefalea por uso excesivo de medicamentos usando anticuerpos anti-cgrp o anti-cgrp-r.
Stoitzner et al. Human skin dendritic cells can be targeted in situ by intradermal injection of antibodies against lectin receptors
MX2022009100A (es) Proteinas de fusion fc heterodimericas il15/il15r alfa para el tratamiento de cancer.
Sperling et al. Facts and hopes in multiple myeloma immunotherapy
AR115721A1 (es) Anticuerpos que comprenden un polipéptido insertado en la región marco 3
MX2021013825A (es) Procedimientos de uso de inmunoconjugados anti-cd79b para tratar el linfoma folicular.
MX2021004916A (es) Nuevas composiciones proteicas de diseño idóneo.
MX2021009079A (es) Metodos para tratar el mieloma multiple.
MX2022013251A (es) Compuestos de heteroaril carboxamida de 5 miembros para el tratamiento de vhb.
MX2021002208A (es) Regimenes de dosificacion de la proteina de fusion de fc y dominio extracelular del cd80.
WO2024069240A3 (fr) Thérapie de combinaison de protéines de fusion se liant à cd38
TW202430548A (zh) Ｃｄ３８結合融合蛋白組合療法
MX2021007047A (es) Formulaciones de anticuerpos.
WO2020180712A8 (fr) Anticorps anti-tnfr2 et leurs utilisations
MX2018010836A (es) Conformeros abiertos hla-b57.
WO2024073716A3 (fr) Thérapie combinatoire de protéines de fusion se liant à cd38
JOP20210247A1 (ar) علاج الصداع باستخدام أجسام مضادة لـ cgrp
MX2021003734A (es) Métodos de tratamiento del linfoma de linfocitos t periférico mediante terapia con conjugado fármaco-anticuerpo anti-cd30.
MX2016009887A (es) Procedimiento para el tratamiento de enfermedades infecciosas utilizando una composicion que comprende inmunoglobulina m (igm) derivada de plasma.
MX2023010567A (es) Variantes de anticuerpos no activadoras.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23828792

Country of ref document: EP

Kind code of ref document: A2